;PMID: 9143866
;source_file_1787.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..144] = [t:44..144]
;2)section:[e:148..163] = [t:148..163]
;3)section:[e:167..241] = [t:167..241]
;4)sentence:[e:245..255] = [t:245..255]
;5)sentence:[e:256..342] = [t:256..342]
;6)sentence:[e:343..481] = [t:343..481]
;7)sentence:[e:482..490] = [t:482..490]
;8)sentence:[e:491..620] = [t:491..620]
;9)sentence:[e:621..718] = [t:621..718]
;10)sentence:[e:719..998] = [t:719..998]
;11)sentence:[e:999..1174] = [t:999..1174]
;12)sentence:[e:1175..1346] = [t:1175..1346]
;13)sentence:[e:1347..1358] = [t:1347..1358]
;14)sentence:[e:1359..1740] = [t:1359..1740]
;15)section:[e:1744..1788] = [t:1744..1788]

;section 0 Span:0..38
;Eur J Clin Pharmacol. 1997;52(1):41-7.
(SEC
  (FRAG (NNP:[0..3] Eur) (NNP:[4..5] J) (NNP:[6..10] Clin)
        (NNP:[11..20] Pharmacol) (.:[20..21] .) (CD:[22..30] 1997;52-LRB-)
        (CD:[30..31] 1) (-RRB-:[31..32] -RRB-) (::[32..33] :) (CD:[33..35] 41)
        (HYPH:[35..36] -) (CD:[36..38] 7.)))

;sentence 1 Span:44..144
;Different effects of inhibitors on the O- and N-demethylation of codeine in 
;human liver microsomes.
;[65..75]:substance:"inhibitors"
;[109..116]:substance:"codeine"
(SENT
  (NP-HLN
    (NP (JJ:[44..53] Different) (NNS:[54..61] effects))
    (PP (IN:[62..64] of)
      (NP (NNS:[65..75] inhibitors)))
    (PP (IN:[76..78] on)
      (NP
        (NP (DT:[79..82] the)
          (NML (NN:[83..84] O) (HYPH:[84..85] -)
            (NML-1 (-NONE-:[85..85] *P*)))
          (CC:[86..89] and)
          (NML (NN:[90..91] N) (HYPH:[91..92] -)
            (NML-1 (NN:[92..105] demethylation))))
        (PP (IN:[106..108] of)
          (NP (NN:[109..116] codeine)))))
    (PP-LOC (IN:[117..119] in)
      (NP (JJ:[121..126] human) (NN:[127..132] liver)
          (NNS:[133..143] microsomes)))
    (.:[143..144] .)))

;section 2 Span:148..163
;Yue QY, Sawe J.
(SEC
  (FRAG (NNP:[148..151] Yue) (NNP:[152..154] QY) (,:[154..155] ,)
        (NNP:[156..160] Sawe) (NNP:[161..163] J.)))

;section 3 Span:167..241
;Department of Clinical Pharmacology, Huddinge University Hospital, Sweden.
(SEC
  (FRAG (NNP:[167..177] Department) (IN:[178..180] of) (NNP:[181..189] Clinical)
        (NNP:[190..202] Pharmacology) (,:[202..203] ,) (NNP:[204..212] Huddinge)
        (NNP:[213..223] University) (NNP:[224..232] Hospital) (,:[232..233] ,)
        (NNP:[234..240] Sweden) (.:[240..241] .)))

;sentence 4 Span:245..255
;OBJECTIVE:
(SENT
  (NP (NN:[245..254] OBJECTIVE) (::[254..255] :)))

;sentence 5 Span:256..342
;The O- and N-demethylation of codeine is catalysed by CYP2D6 and  CYP3A4
;respectively.
;[286..293]:substance:"codeine"
;[310..316]:cyp450:"CYP2D6"
;[322..328]:cyp450:"CYP3A4"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[256..259] The)
        (NML
          (NML (NN:[260..261] O) (HYPH:[261..262] -)
            (NML-1 (-NONE-:[262..262] *P*)))
          (CC:[263..266] and)
          (NML (NN:[267..268] N) (HYPH:[268..269] -)
            (NML-1 (NN:[269..282] demethylation)))))
      (PP (IN:[283..285] of)
        (NP (NN:[286..293] codeine))))
    (VP (VBZ:[294..296] is)
      (VP (VBN:[297..306] catalysed)
        (NP-2 (-NONE-:[306..306] *))
        (PP (IN:[307..309] by)
          (NP-LGS (NN:[310..316] CYP2D6) (CC:[317..320] and)
                  (NN:[322..328] CYP3A4)))
        (ADVP (RB:[329..341] respectively))))
    (.:[341..342] .)))

;sentence 6 Span:343..481
;The formation rates of morphine by O-demethylation and  norcodeine by
;N-demethylation were studied in two sets of human liver  microsomes.
;[366..374]:substance:"morphine"
;[399..409]:substance:"norcodeine"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[343..346] The) (NN:[347..356] formation) (NNS:[357..362] rates))
      (PP (IN:[363..365] of)
        (NP
          (NP
            (NP (NN:[366..374] morphine))
            (PP (IN:[375..377] by)
              (NP (NN:[378..393] O-demethylation))))
          (CC:[394..397] and)
          (NP
            (NP (NN:[399..409] norcodeine))
            (PP (IN:[410..412] by)
              (NP (NN:[413..428] N-demethylation)))))))
    (VP (VBD:[429..433] were)
      (VP (VBN:[434..441] studied)
        (NP-1 (-NONE-:[441..441] *))
        (PP-LOC (IN:[442..444] in)
          (NP
            (NP (CD:[445..448] two) (NNS:[449..453] sets))
            (PP (IN:[454..456] of)
              (NP (JJ:[457..462] human) (NN:[463..468] liver)
                  (NNS:[470..480] microsomes)))))))
    (.:[480..481] .)))

;sentence 7 Span:482..490
;RESULTS:
(SENT
  (NP (NNS:[482..489] RESULTS) (::[489..490] :)))

;sentence 8 Span:491..620
;Relatively high K(m) values were found for both O- and  N-demethylations,
;suggesting a low affinity to the corresponding enzymes.
;[507..511]:quantitative-name:"K(m)"
;[612..619]:substance:"enzymes"
(SENT
  (S
    (NP-SBJ-2
      (ADJP (RB:[491..501] Relatively) (JJ:[502..506] high))
      (NN:[507..511] K-LRB-m-RRB-) (NNS:[512..518] values))
    (VP (VBD:[519..523] were)
      (VP (VBN:[524..529] found)
        (NP-2 (-NONE-:[529..529] *))
        (PP (IN:[530..533] for)
          (NP (CC:[534..538] both)
            (NP
              (NP (NN:[539..540] O) (HYPH:[540..541] -)
                (NML-1 (-NONE-:[541..541] *P*)))
              (CC:[542..545] and)
              (NP (NN:[547..548] N) (HYPH:[548..549] -)
                (NML-1 (NNS:[549..563] demethylations))))))
        (,:[563..564] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[564..564] *))
          (VP (VBG:[565..575] suggesting)
            (NP
              (NP (DT:[576..577] a) (JJ:[578..581] low) (NN:[582..590] affinity))
              (PP (TO:[591..593] to)
                (NP (DT:[594..597] the) (VBG:[598..611] corresponding)
                    (NNS:[612..619] enzymes))))))))
    (.:[619..620] .)))

;sentence 9 Span:621..718
;The  inhibitory effects of various drugs were found to be different for O-
;and  N-demethylations.
;[656..661]:substance:"drugs"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[621..624] The) (JJ:[626..636] inhibitory)
          (NNS:[637..644] effects))
      (PP (IN:[645..647] of)
        (NP (JJ:[648..655] various) (NNS:[656..661] drugs))))
    (VP (VBD:[662..666] were)
      (VP (VBN:[667..672] found)
        (S
          (NP-SBJ-2 (-NONE-:[672..672] *))
          (VP (TO:[673..675] to)
            (VP (VB:[676..678] be)
              (ADJP-PRD (JJ:[679..688] different)
                (PP (IN:[689..692] for)
                  (NP
                    (NP (NN:[693..694] O) (HYPH:[694..695] -)
                      (NML-1 (-NONE-:[695..695] *P*)))
                    (CC:[696..699] and)
                    (NP (NN:[701..702] N) (HYPH:[702..703] -)
                      (NML-1 (NNS:[703..717] demethylations)))))))))))
    (.:[717..718] .)))

;sentence 10 Span:719..998
;The substrates of CYP2D6 such as thioridazine, amitriptyline  and metoprolol
;inhibited the O-demethylation of codeine preferentially, while  the
;substrates of CYP3A4 such as cyclosporine A, midazolam and erythromycin were 
;all strong inhibitors of the N-demethylation of codeine.
;[723..733]:substance:"substrates"
;[737..743]:cyp450:"CYP2D6"
;[752..764]:substance:"thioridazine"
;[766..779]:substance:"amitriptyline"
;[785..795]:substance:"metoprolol"
;[829..836]:substance:"codeine"
;[864..874]:substance:"substrates"
;[878..884]:cyp450:"CYP3A4"
;[893..907]:substance:"cyclosporine A"
;[909..918]:substance:"midazolam"
;[923..935]:substance:"erythromycin"
;[953..963]:substance:"inhibitors"
;[990..997]:substance:"codeine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[719..722] The) (NNS:[723..733] substrates))
      (PP (IN:[734..736] of)
        (NP (NN:[737..743] CYP2D6)))
      (PP (JJ:[744..748] such) (IN:[749..751] as)
        (NP (NN:[752..764] thioridazine) (,:[764..765] ,)
            (NN:[766..779] amitriptyline) (CC:[781..784] and)
            (NN:[785..795] metoprolol))))
    (VP (VBD:[796..805] inhibited)
      (NP
        (NP (DT:[806..809] the) (NN:[810..825] O-demethylation))
        (PP (IN:[826..828] of)
          (NP (NN:[829..836] codeine))))
      (ADVP (RB:[837..851] preferentially))
      (,:[851..852] ,)
      (SBAR-ADV (IN:[853..858] while)
        (S
          (NP-SBJ
            (NP (DT:[860..863] the) (NNS:[864..874] substrates))
            (PP (IN:[875..877] of)
              (NP (NN:[878..884] CYP3A4)))
            (PP (JJ:[885..889] such) (IN:[890..892] as)
              (NP
                (NP (NN:[893..905] cyclosporine) (NN:[906..907] A))
                (,:[907..908] ,)
                (NP (NN:[909..918] midazolam))
                (CC:[919..922] and)
                (NP (NN:[923..935] erythromycin)))))
          (VP (VBD:[936..940] were) (DT:[942..945] all)
            (NP-PRD
              (NP (JJ:[946..952] strong) (NNS:[953..963] inhibitors))
              (PP (IN:[964..966] of)
                (NP
                  (NP (DT:[967..970] the) (NN:[971..986] N-demethylation))
                  (PP (IN:[987..989] of)
                    (NP (NN:[990..997] codeine))))))))))
    (.:[997..998] .)))

;sentence 11 Span:999..1174
;Quinidine and  lignocaine, although they are substrates of CYP3A, showed
;preferential  inhibition over the O-demethylation of codeine, suggesting a
;low affinity to the  CYP3A.
;[999..1008]:substance:"Quinidine"
;[1014..1024]:substance:"lignocaine"
;[1044..1054]:substance:"substrates"
;[1058..1063]:cyp450:"CYP3A"
;[1125..1132]:substance:"codeine"
;[1168..1173]:cyp450:"CYP3A"
(SENT
  (S
    (NP-SBJ (NN:[999..1008] Quinidine) (CC:[1009..1012] and)
            (NN:[1014..1024] lignocaine))
    (,:[1024..1025] ,)
    (SBAR-ADV (IN:[1026..1034] although)
      (S
        (NP-SBJ (PRP:[1035..1039] they))
        (VP (VBP:[1040..1043] are)
          (NP-PRD
            (NP (NNS:[1044..1054] substrates))
            (PP (IN:[1055..1057] of)
              (NP (NN:[1058..1063] CYP3A)))))))
    (,:[1063..1064] ,)
    (VP (VBD:[1065..1071] showed)
      (NP
        (NP (JJ:[1072..1084] preferential) (NN:[1086..1096] inhibition))
        (PP (IN:[1097..1101] over)
          (NP
            (NP (DT:[1102..1105] the) (NN:[1106..1121] O-demethylation))
            (PP (IN:[1122..1124] of)
              (NP (NN:[1125..1132] codeine))))))
      (,:[1132..1133] ,)
      (S-MNR
        (NP-SBJ (-NONE-:[1133..1133] *))
        (VP (VBG:[1134..1144] suggesting)
          (NP
            (NP (DT:[1145..1146] a) (JJ:[1147..1150] low)
                (NN:[1151..1159] affinity))
            (PP (TO:[1160..1162] to)
              (NP (DT:[1163..1166] the) (NN:[1168..1173] CYP3A)))))))
    (.:[1173..1174] .)))

;sentence 12 Span:1175..1346
;Methadone and dextropropoxyphene showed a preferential inhibition of  CYP2D6
;over CYP3A, while theophylline did not inhibit the O- or N-demethylation  to
;a greater extent.
;[1175..1184]:substance:"Methadone"
;[1189..1207]:substance:"dextropropoxyphene"
;[1245..1251]:cyp450:"CYP2D6"
;[1257..1262]:cyp450:"CYP3A"
;[1270..1282]:substance:"theophylline"
(SENT
  (S
    (NP-SBJ (NN:[1175..1184] Methadone) (CC:[1185..1188] and)
            (NN:[1189..1207] dextropropoxyphene))
    (VP (VBD:[1208..1214] showed)
      (NP
        (NP (DT:[1215..1216] a) (JJ:[1217..1229] preferential)
            (NN:[1230..1240] inhibition))
        (PP (IN:[1241..1243] of)
          (NP (NN:[1245..1251] CYP2D6)))
        (PP (IN:[1252..1256] over)
          (NP (NN:[1257..1262] CYP3A))))
      (,:[1262..1263] ,)
      (SBAR-ADV (IN:[1264..1269] while)
        (S
          (NP-SBJ (NN:[1270..1282] theophylline))
          (VP (VBD:[1283..1286] did) (RB:[1287..1290] not)
            (VP (VB:[1291..1298] inhibit)
              (NP (DT:[1299..1302] the)
                (NML
                  (NML (NN:[1303..1304] O) (HYPH:[1304..1305] -)
                    (NML-1 (-NONE-:[1305..1305] *P*)))
                  (CC:[1306..1308] or)
                  (NML (NN:[1309..1310] N) (HYPH:[1310..1311] -)
                    (NML-1 (NN:[1311..1324] demethylation)))))
              (PP (TO:[1326..1328] to)
                (NP (DT:[1329..1330] a) (JJR:[1331..1338] greater)
                    (NN:[1339..1345] extent))))))))
    (.:[1345..1346] .)))

;sentence 13 Span:1347..1358
;CONCLUSION:
(SENT
  (NP (NN:[1347..1357] CONCLUSION) (::[1357..1358] :)))

;sentence 14 Span:1359..1740
;It seems that there was a good correspondence  between the capacity of drugs
;to inhibit the O- and N-demethylation of codeine  in human liver microsomes
;and their apparent metabolism by CYP2D6 or CYP3A4,  respectively in vivo in
;man, suggesting that this in vitro inhibition test may  be a useful screen
;for drugs which interact with these two important  drug-metabolising
;enzymes.
;[1430..1435]:substance:"drugs"
;[1477..1484]:substance:"codeine"
;[1545..1551]:cyp450:"CYP2D6"
;[1555..1561]:cyp450:"CYP3A4"
;[1667..1672]:substance:"drugs"
;[1714..1718]:substance:"drug"
;[1732..1739]:cyp450:"enzymes"
(SENT
  (S
    (NP-SBJ (PRP:[1359..1361] It))
    (VP (VBZ:[1362..1367] seems)
      (SBAR (IN:[1368..1372] that)
        (S
          (NP-SBJ (EX:[1373..1378] there))
          (VP (VBD:[1379..1382] was)
            (NP-PRD
              (NP (DT:[1383..1384] a) (JJ:[1385..1389] good)
                  (NN:[1390..1404] correspondence))
              (PP (IN:[1406..1413] between)
                (NP
                  (NP
                    (NP (DT:[1414..1417] the) (NN:[1418..1426] capacity)
                      (S-3 (-NONE-:[1426..1426] *ICH*)))
                    (PP (IN:[1427..1429] of)
                      (NP (NNS:[1430..1435] drugs)))
                    (S-3
                      (NP-SBJ (-NONE-:[1435..1435] *))
                      (VP (TO:[1436..1438] to)
                        (VP (VB:[1439..1446] inhibit)
                          (NP
                            (NP (DT:[1447..1450] the)
                              (NML
                                (NML (NN:[1451..1452] O) (HYPH:[1452..1453] -)
                                  (NML-2 (-NONE-:[1453..1453] *P*)))
                                (CC:[1454..1457] and)
                                (NML (NN:[1458..1459] N) (HYPH:[1459..1460] -)
                                  (NML-2 (NN:[1460..1473] demethylation)))))
                            (PP (IN:[1474..1476] of)
                              (NP (NN:[1477..1484] codeine)))
                            (PP-LOC (IN:[1486..1488] in)
                              (NP (JJ:[1489..1494] human)
                                  (NN:[1495..1500] liver)
                                  (NNS:[1501..1511] microsomes))))))))
                  (CC:[1512..1515] and)
                  (NP
                    (NP (PRP$:[1516..1521] their) (JJ:[1522..1530] apparent)
                        (NN:[1531..1541] metabolism))
                    (PP (IN:[1542..1544] by)
                      (NP
                        (NP (NN:[1545..1551] CYP2D6) (CC:[1552..1554] or)
                            (NN:[1555..1561] CYP3A4))
                        (,:[1561..1562] ,)
                        (ADVP (RB:[1564..1576] respectively))))
                    (ADVP (FW:[1577..1579] in) (FW:[1580..1584] vivo))
                    (PP-LOC (IN:[1585..1587] in)
                      (NP (NN:[1588..1591] man)))))))
            (,:[1591..1592] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1592..1592] *))
              (VP (VBG:[1593..1603] suggesting)
                (SBAR (IN:[1604..1608] that)
                  (S
                    (NP-SBJ (DT:[1609..1613] this)
                      (NML (FW:[1614..1616] in) (FW:[1617..1622] vitro))
                      (NN:[1623..1633] inhibition) (NN:[1634..1638] test))
                    (VP (MD:[1639..1642] may)
                      (VP (VB:[1644..1646] be)
                        (NP-PRD
                          (NP (DT:[1647..1648] a) (JJ:[1649..1655] useful)
                              (NN:[1656..1662] screen))
                          (PP (IN:[1663..1666] for)
                            (NP
                              (NP (NNS:[1667..1672] drugs))
                              (SBAR
                                (WHNP-1 (WDT:[1673..1678] which))
                                (S
                                  (NP-SBJ-1 (-NONE-:[1678..1678] *T*))
                                  (VP (VBP:[1679..1687] interact)
                                    (PP-CLR (IN:[1688..1692] with)
                                      (NP (DT:[1693..1698] these)
                                          (CD:[1699..1702] two)
                                          (JJ:[1703..1712] important)
                                        (ADJP (NN:[1714..1718] drug)
                                              (HYPH:[1718..1719] -)
                                              (VBG:[1719..1731] metabolising))
                                        (NNS:[1732..1739] enzymes)))))))))))))))))))
    (.:[1739..1740] .)))

;section 15 Span:1744..1788
;PMID: 9143866 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1744..1748] PMID) (::[1748..1749] :) (CD:[1750..1757] 9143866)
        (NN:[1758..1759] -LSB-) (NNP:[1759..1765] PubMed) (::[1766..1767] -)
        (NN:[1768..1775] indexed) (IN:[1776..1779] for)
        (NNP:[1780..1788] MEDLINE-RSB-)))
